Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
作者信息
Qiu Hai-Bo
机构信息
Department of Gastric Surgery, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
出版信息
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.
Abstract
摘要
相似文献
1
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.
2
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
3
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
4
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Cancer Immunol Immunother. 2024 May 7;73(7):119. doi: 10.1007/s00262-024-03677-7.
5
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811.
Chin Clin Oncol. 2024 Aug;13(4):59. doi: 10.21037/cco-24-28. Epub 2024 Jun 6.
6
Current status of ramucirumab in gastroesophageal adenocarcinoma.
Future Oncol. 2017 Aug;13(18):1585-1592. doi: 10.2217/fon-2016-0556. Epub 2017 Apr 24.
7
[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].
Bull Cancer. 2024 Feb;111(2):130-132. doi: 10.1016/j.bulcan.2023.11.004. Epub 2023 Dec 8.
8
Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
Anticancer Drugs. 2024 Aug 1;35(7):666-671. doi: 10.1097/CAD.0000000000001607. Epub 2024 Mar 22.
9
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].
Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.
10
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
引用本文的文献
1
Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives.
Front Immunol. 2025 May 14;16:1599908. doi: 10.3389/fimmu.2025.1599908. eCollection 2025.
2
Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers.
World J Gastrointest Oncol. 2024 Apr 15;16(4):1613-1625. doi: 10.4251/wjgo.v16.i4.1613.
3
PD-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near infrared-II diagnostic imaging and radiosensitization.
Front Bioeng Biotechnol. 2023 Jun 7;11:1224339. doi: 10.3389/fbioe.2023.1224339. eCollection 2023.
4
Comparison of McKeown Minimally Invasive Esophagectomy vs sweet esophagectomy for esophageal squamous cell carcinoma: A retrospective study.
Front Oncol. 2022 Dec 19;12:1009315. doi: 10.3389/fonc.2022.1009315. eCollection 2022.
5
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.
Front Immunol. 2022 Aug 3;13:920021. doi: 10.3389/fimmu.2022.920021. eCollection 2022.
本文引用的文献
1
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res. 2020 Sep 1;26(17):4542-4550. doi: 10.1158/1078-0432.CCR-19-3561. Epub 2020 Jun 19.
2
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000437.
3
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
The immune landscape of esophageal cancer.
Cancer Commun (Lond). 2019 Nov 26;39(1):79. doi: 10.1186/s40880-019-0427-z.
5
National trend of gastric cancer mortality in China (2003-2015): a population-based study.
Cancer Commun (Lond). 2019 May 2;39(1):24. doi: 10.1186/s40880-019-0372-x.
6
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Cancer Commun (Lond). 2019 Apr 29;39(1):22. doi: 10.1186/s40880-019-0368-6.
7
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer.
Cancer Commun (Lond). 2019 Mar 18;39(1):10. doi: 10.1186/s40880-019-0349-9.
8
Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer.
Anticancer Res. 2018 Oct;38(10):5569-5580. doi: 10.21873/anticanres.12891.
9
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
Cancer Immunol Immunother. 2018 Jul;67(7):1079-1090. doi: 10.1007/s00262-018-2160-x. Epub 2018 Apr 23.
10
SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016).
Clin Transl Oncol. 2016 Dec;18(12):1179-1186. doi: 10.1007/s12094-016-1577-y. Epub 2016 Nov 29.
Zotero 插件